Phaseline

Companies › SURGE Therapeutics

SURGE Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STM-416p–Phase 1Prostate CancerDec 2026
STM-416
Unclear - mechanism not disclosed in registry
–Phase 1Non-muscle-invasive Bladder Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05710848STM-416Phase 1Non-muscle-invasive Bladder CancerOncologyMay 2026
NCT06450106STM-416pPhase 1Prostate CancerOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.